key: cord-0952807-06e595u4 authors: Chowdhuryz, Neehasri Kumar; Deepika; Choudhury, Reshma; Sonawane, Gaurav Ambadas; Mavinamar, Shankar; Lyu, Xiaoming; Pandey, Ramendra Pati; Chang, Chung-Ming title: Nanoparticles as an Effective Drug Delivery System in Covid-19 date: 2021-09-09 journal: Biomed Pharmacother DOI: 10.1016/j.biopha.2021.112162 sha: 33e677ce6fc8442bfd824d1c396499b26142de84 doc_id: 952807 cord_uid: 06e595u4 BACKGROUND: The global healthcare sector has been dealing with a situation known as a novel severe acute respiratory syndrome (SARS-CoV-2) since the end of 2019. Covid-19 is an acronym for Covid-19 (Coronavirus Disease- 2019). It causes a respiratory infection that includes cold, sneezing and coughing, and pneumonia. In the case of an animal, it causes diarrhea and upper respiratory diseases. Covid-19 transmitted human to human via airborne droplets. First Covid-19 emerged in Wuhan market China and it spread rapidly throughout the World. As we know nanoparticles are a novel drug delivery system. They have various advantageous effects like increasing the efficacy of the drug, safety, etc. In this review, we study about the nanoparticles and summarize how it is effective during drug delivery system in Covid-19. Chitosan is a much focused biopolymeric nanoparticle. It delivers drugs to the specific target site. In a recent health crisis, chitosan nanoparticles are one of the ways to release drugs of Covid-19, and specifically in the lungs of the affected patients. We studied and extracted our data from various research papers, review papers, and some other articles. OBJECTIVE: The main goal is to study the nanoparticles and their future aspects which is an effective drug delivery system in Covid-19. METHODS: The bibliographic search was done through a systematic search. The terms “Nanoparticles”, “Covid-19 ”, “Drug delivery” etc. were used to search the databases/search engines like “Google Scholar”, “NCBI”, “PubMed”, “Science Direct” etc. These databases and search engines used here perform the limited criteria of search to conduct a systematic literature survey for the study and report writing. All the text from the articles and research papers were studied and analyzed. The various articles and research papers were used in writing this report and all of which are mentioned in the reference section of this report. CONCLUSION: Our current studies reveal that nanoparticles may prove very helpful in the delivery of drugs for Covid-19 treatment. Many cases showed that patients, where drugs are delivered with the help of nanoparticles, produced very few side effects. A globally spreading disease known as a novel severe acute respiratory syndrome called coronavirus 2 (SARS-CoV-2), abbreviated as COVID-19 pandemic starts spreading from Wuhan in China (as data suggested). On 30 th January 2020, WHO declared COVID-19 as a pandemic. The world is dealing with the worst era of the pandemic at a very high infectious and death rate up to 6.89% because of the (data till April 27) . The deadliest coronavirus belongs to the Nidovirales order, including Coronaviridae, Arteriviridae, Mesoniviridae, and Roniviridae families. Coronaviruses belong to positive-sense mRNA virus and may be characterized by a usually large RNA genome, club-like projections from the surface, and a very unique replication strategy which also shows a mutation in some strains and lethal to human beings²¹. An effective vaccine is still not available to treat this disease hereby it is very important to deliver the drug at a suitable place at right time to reduce the mortality rate and cure infected people⁶⁶. Nanoparticles show a remarkable difference in the culture medium of coronavirus before and during infection with coronavirus. Nanoparticles also show a remarkable inhibition activity or viral life cycle i.e. 55 hours⁴. Nanotechnology can be defined as the study, manipulation, control, design, synthesis, and creation of different systems through control of matter at nm (nanometer scale) 1-100 nm where 1nm=10 -9 i.e. at a molecular and atomic level, utilization of novel phenomenon and properties at that scale⁵⁸. Nanoparticle drug formulations play an important role in pulmonary drug delivery. In dispersed liquid droplets form and as well as in dry powder form different nanoparticles complex shows advantageous result involving the high potential for drug delivery(intracellular), and enhancing dissolution properties makes very uncourageous results to deliver the drug through the lungs⁵. Modern advances of science in drug delivery are very focused upon polymers (chain of monomers) and their types as they exert salient features and distinct biological functions. The latest approaches in intracellular drug delivery include various polymer-drug conjugates, protein polymer, and stimuli-responsive polymer systems of polymers in drug delivery³⁹. Biopolymeric nanoparticles (chitosan and gelatin) can be used to deliver different drugs e.g. gelatin nanoparticles possessing hydrophobicity and hydrophilicity used for delivery of different drugs including doxorubicin³⁶ and ophthalmic drug¹⁹. Similarly, to deliver the drug in J o u r n a l P r e -p r o o f the case of The loading of the drug on the nanoparticle is defined and based upon the amount of drug per mass of the polymer (usually mg drug per mg polymer or moles of drug per mg polymer). Different techniques can use for analysis and quantification including HPLC, gel filtration, chromatography, spectroscopy, etc. In the field of Nanotechnology and Nanomedicine, there are large numbers of nanomaterials that are used to deliver drugs having properties like improving solubility, extending formulation's action, different degrees of lipophilicity, or hydrophilicity, less toxicity. Nanoparticles drug delivery systems possess different physicochemical properties such as surface properties, shape, size, treatment efficacy, drug system release, and loading, etc. Surface properties of Nanoparticles influenced biocompatibility, biodistribution, and pharmacokinetics of drug molecule²⁸. Nanoparticle shape influenced cellular internalization of nanoparticles and biodistribution determination²⁷. The size of the nanoparticle can also play a major role in influencing protein adsorption, cellular internalization mechanism, and biodistribution⁵². Controlled drug release: A significant release of drug cargos including understanding matrix erosion, diffusion, and desorption of linked drug⁸⁰. Drug loading can reduce toxicity from the carrier by reducing the amount of drug carrier used⁷⁸. Biopolymers can be defined as biomolecular monomeric units which are covalently attached to form a large molecule⁴⁵. They are more feasible and suitable as they are not carcinogenic²⁰. There are different kinds of biopolymers that can be used in effective drug delivery and preparation of biodegradable nanoparticles including heparin, soluble starch, gelatin, PVP(Polyvinyl-pyrrolidone), PVA(Poly-Vinyl Acetate), cellulose, gelatin, chitosan and so on⁴⁵. Out of all these Chitosan is a much focused and researched biopolymeric nanoparticle. Chitosan is a functional amino polymer having Chitin as a precursor and second most commonly found polysaccharide in nature after cellulose⁷⁸. Chitosan-based NPS have been various applications in different diseases including the brain, ocular infections, pulmonary diseases, gastrointestinal diseases, and cancer⁴⁴. Besides oral, nasal, pulmonary, or vaginal route for drug delivery mucosal route is more feasible and attention gaining part with low toxicity, appropriate physical properties, and good muco-adhesion⁵⁴. J o u r n a l P r e -p r o o f Chitosan can deliver drugs by following mechanisms (i) swelling (ii) Diffusion (iii) erosion. In pulmonary drug delivery, drugs can directly deliver to the lungs which may provide a large surface area which added as an advantage for chitosan nanoparticles hence can be used in the treatment of COVID-19⁵⁶. The various layer of the lungs including the epithelial lining, mucosal layer, epidermal cells, and branchias mucosal layer can limit drug delivery via lung⁵⁷. Bioavanta Bosti, developed Chitosan polymeric technology in COVID-19 patients develops Novochizol⁵⁶. There are various methods used for the synthesis of the bio nanoparticle-created DDS, for example, spray-drying³⁴, desolvation²⁴, electro spraying⁶, layer-by-layer self-assembly surfactant Assemblies⁶⁴, supercritical fluid extraction⁵⁹,⁷⁴, microemulsion⁸,³⁶ and freeze-drying³²,⁷⁵. Among all the listed methods, all method has its advantages and drawbacks also. Between these, desolvation is the simple method for the manufacturing of protein-based nanoparticles by solvents such as ethanol or acetone. In this desolvation method, biopolymeric nanoparticles are manufactured by the mixing of solvents in an aqueous solution by constant stirring. The dimensions of the nanoparticles can be maintained by controlling the flow rate of the amount or volume of a desolvating agent³³ , ⁶⁹. Electrospray technique is a moderate, single step and multipurpose technique with more yield and reliability. To produce particles from size nanometer/micrometer range it uses the electrostatic force to break liquid from a macroscopic mass⁴² , ⁴⁶. Freeze-drying is an appropriate method for the compounds which are heat and pressure-sensitive, dried porous particles are obtained when solvents are sublimed. But this method has a drawback, it is a time-consuming and costly method, and the obtained particle having size is generally larger³⁸ , ⁶⁷. The new layer-by-layer self-assembly method multilayer can be useful for sequential multilayer film formation, which is completed from side to side hydrophobic, electrostatic interactions, and hydrogen bonding are among the films. The nanoscopic features like thickness, surface characteristics, and composition for a film can be achieved by interactions that help to deposit alternate layers of oppositely charged biomaterials and supply precise control to create³⁰ , ⁴¹. Finally, by using emulsifiers or surfactants microemulsions can be synthesized or prepared by dispersing a biopolymer in two immiscible J o u r n a l P r e -p r o o f phases of liquids. Nanomaterials achieved by this method are normally optically transparent, they have high drug solubilizing property, isotropic, and thermodynamically stable ( Fig. 1 )¹¹ , ³⁶. Chitosan NP ( nanoparticles) displayed a stamped propensity to aggregate in various tumors. One of the potential explanations behind this marvel might be the brokenness of tumor vasculature. Nano-sized particles can be controlled intravenously because the distance across the littlest blood hair is around 4 µm. Chitosan polymer groups significantly lower harmfulness than poly-Llysine and PEI is less immunogenic and needs mutational potential. It upgrades the vehicle of medication across cell film. To build the transfection efficiency, cells focusing on ligands were joined to the chitosan particles. Chitosan-TPP nanoparticles show a lot of potential as reasonable vector contenders for more secure and financially savvy siRNA conveyance. The chitosan nanoparticles have additionally been utilized as non-viral vectors for the quality conveyance or as conveyance transporters for protein particles. Chitosan has broadly been investigated for the J o u r n a l P r e -p r o o f application for DNA mucosal immunizations. A chitosan-based DNA flu antibody has been created by Illum et al. that indicated a high counteracting agent level in mice after intranasal organization. The relationship of immunizations to a portion of the particulate frameworks as nanoparticles has appeared to upgrade the antigen take-up by mucosal lymphoid tissues, in this manner actuating solid foundational and mucosal safe reactions against the antigens.Since chitosan is a low poisonous material, ophthalmic definition dependent on chitosan has displayed a phenomenal resistance after applied chitosan onto the hare's corneal surface. Other than utilizing chitosan NP to improve tranquilizes transport employing visual, chitosan-covered nanoparticles is likewise used as it displays capacity to upgrade the corneal infiltration 47 . From the end of 2019 to yet, the global health sector is passing through a situation that is novel severe acute respiratory syndrome, which is called Coronavirus 2 (SARS-CoV-2)⁶⁶. It is abbreviated as COVID-19 (Coronavirus Disease 2019)⁶⁶. This virus belongs to the family Coronaviridae, the order is Nidovirals and the genus is coronavirus²⁹ (Fig. 2) . These viruses are a group of related RNA viruses and it causes disease in the animals or humans body²⁹. This group of viruses causes some respiratory and gastrointestinal infection⁵⁰. It is a zoonotic virus that causes illness and it ranging from the common cold to severe respiratory diseases. Zoonotic virus means these viruses are transmitted from animals to humans (labmanager.com/Lab health and Safety, 2020). Novel coronavirus disease 2019 that is COVID-19, results in a human infection that confirms some signs and symptoms like fever, fatigue, dyspnea, and lymphopenia⁵⁰. In some cases, human infections may lead to some complications like Pneumonia, and cause death⁵⁰. ‗Corona' name represents the crown-like spikes on the outer surface of the virus so, its name is a coronavirus 62 (Fig.4) . This virus is minute in size and ranges from 65-125nm in diameter. It contains a single-stranded RNA as a nucleic material and its size ranging from 26 to 32kbs in length⁶². The coronavirus family has four subgroups and these are alpha, beta, gamma, and delta coronavirus⁶². The recent COVID-19 virus is a member of the beta group of coronaviruses⁶². From the end of 2019, COVID-19 has caused mortality and morbidity worldwide¹². infection is associated with increasing numbers day by day. COVID-19 infectious patients showed higher leucocyte numbers, abnormal respiratory findings, increased levels of plasma proinflammatory cytokines⁵⁵. Management of COVID-19 is extremely challenging because some cases showed high infectivity of the virus, but lack of effective antivirals and vaccines, and potentially there exists a large asymptomatic population¹². According to Genome Sequencing, the COVID-19 (SARS-CoV-2) is partially related with the SARS-CoV (approx. 79% similarity) and MERS-CoV (approx. 50% similarity)⁴³. Similar to SARS-CoV, SARS-CoV-2 also uses angiotensin-converting enzyme 2 (ACE2) as its main receptor⁴³. It is broadly expressed in vascular endothelium, respiratory epithelium, alveolar monocytes, and macrophages⁴³. Here disease. Studies to facilitate the specific therapeutics for control the virus minimize pulmonary injuries or optimize the immune responses¹². COVID-19 is an exceptionally deadly respiratory disease that is quickly spreading and has caused universal tension. At present, it is analyzed by identifying the SARS-CoV-2 nucleic corrosive through continuous RT-PCR (qRT-PCR). Nanoparticles are small however it has a huge surfaceto-volume proportion, which gives them remarkable and extraordinary highlights in COVID-19. (Table 2) . Now and again, the gatherings will send reagents or reagent blenders arranged in their research facilities, with or without related charges. It is emphatically prescribed to contact the researcher 49 . Table 4 ). Following are the enlisted antiviral drugs that are possible treatment of COVID-19. The structure of antiviral drugs and their rationale of use is described in the following table ( Table 5 ). Remdesivir is a broadspectrum antiviral with in vitro activity against coronaviruses² , ⁹ , ¹⁸ , ²⁶ , ³⁵ , ⁷⁰ , ⁷². Chloroquine has in vitro activity against SARS-CoV-2 and has immunomodulating properties¹⁵ , ⁷⁰ , ⁷⁷. Hydroxychloroquine has in vitro activity against SARS-CoV-2 and may have immunomodulating properties² , ⁷ , ¹⁵ , ²² , ²³ , ⁶⁰ , ⁷⁰. In vitro and animal model studies show potential activity for other coronaviruses (SARS-CoV and MERS-CoV)¹³ , ¹⁴ , ⁷⁶. Favipiravir is a broadspectrum antiviral with in vitro activity against RNA viruses¹⁵ , ⁶³ , ⁷². The above drugs, have disparate mechanisms of action. Here, a brief insight of all the mechanisms of action of each drug mentioned. Remdesivir is a monophosphoramidate prodrug of remdesivir-triphosphate (RDV-TP), an adenosine analog simple that goes about as an inhibitor of RNA-Dependant RNA polymerases (RdRps). Remdesivir-TP contends with adenosine-triphosphate for incorporation into beginning viral RNA chains. When joined into the viral RNA at position I, RDV-TP ends RNA amalgamation at position i +3 . Since RDV-TP doesn't cause quick chain termination (i.e., 3 extra nucleotides are consolidated after RDV-TP), the drug seems to proofread by viral exoribonuclease (an enzyme idea to excise nucleotide analog inhibitors)² , ⁹ , ¹⁸ , ²⁶ , ³⁵ , ⁷⁰ , ⁷². Mechanisms involved inhibition of viral several enzymes or systems such as viral DNA and RNA polymerase, glycosylation of viral protein, virus assembly, new virus particle transport, and virus discharge. Other mechanisms may also involve ACE2 cellular receptor inhibition, J o u r n a l P r e -p r o o f acidification at the surface of the cell membrane repressing fusion of the virus, and immunomodulation of cytokine release² , ⁷ , ¹⁶ , ²² , ²³ , ⁶⁰ , ⁷⁰. Mechanisms involved inhibition of viral several enzymes or systems such as viral DNA and RNA polymerase, glycosylation of viral protein, virus assembly, new virus particle transport, and virus discharge. Other mechanisms may also involve ACE2 cellular receptor inhibition, acidification at the surface of the cell membrane repressing fusion of the virus, and immunomodulation⁷ , ¹⁶ , ²² , ²³ , ⁶⁰ , ⁷⁰. Lopinavir and ritonavir may bind to Mpro, a key enzyme of coronavirus replication. This inhibits coronavirus activity⁴¹. Favipiravir is an RNA-dependent RNA polymerase (RdRp) inhibitor that inhibits viral transcription¹⁵ , ⁶³ , ⁷². The world is facing a continuous struggle with a much larger potential to spread the deadly and highly infectious SARS-CoV-2. The re-use of some prospective antiviral medications is the main area of investigation from a therapeutic point of view. For suitable safety and pharmacokinetic profile in people, some additional medicines with a considerably higher in vitro and in vivo efficacy against COVID-19 were studied. In its creation and use, however, there are other problems. The coronaviruses are variable RNA viruses. New coronavirus varieties with new structures thus appear easily. For these new coronavirus types, conventional medicines may not be as effective or have just weak effects. Further study may be carried out in order to accomplish multimodal therapies for various antiviral medicines concurrently on-site. The creation of these new forms of antiviral medicine distribution is usually more difficult than the standard system for the delivery of medications. The challenges of large-scale production are amongst the few impediments to the development of this promising technology. The optimized manufacture of the nanocarrier system to encapsulate therapy potential utilizing the quality-by-design method in order to highlight the crucial processing factor and content material characteristics is important. J o u r n a l P r e -p r o o f Furthermore, the design of the innovative drug delivery is critical to an integrated understanding of COVID-19's structural morphology, virulence and transmission. In global health, the SARS-CoV-2 novelknown as the COVID-19 pandemichas the most dangerous effect that affects people in every region and community in the world. The development of COVID-19 diagnostics, treatment, prevention and developing vaccine may play a crucial role in nanotechnology based medicines. Moreover it is important to have time for the encounter of infectious diseases and nano-based materials in comparison with other therapies, as they are not linked to long and strict regulatory issues commonly associated with vaccines, to come to the public earlier. Even in small concentrations and shortening response periods to see if an individual is infected, it is necessary to develop a broad antiviral spectrum of disinfectants with acceptable effectiveness. In addition, it is crucial that monotherapy problems are overcome and that the drug's dose is reduced and its negative effects decreased. Moreover a solution that can reduce the risk of diseases where the viral load is heavily reduced is the development of surface coating with a relatively small surface energy (which can repel, kill or be anti-adhesion to the pathogens). Nano-based materials have the potential to gain a foothold in the face of the current global public health hazard by encouraging the wide-ranging, integrated approaches that are required to manage and control the COVID-19 outbreak at both the local and international levels. Chitosan nanoparticles will be the most emergent field to study drug delivery and novel drug discovery. In pulmonary drug delivery, drugs are administered directly to the lungs, offering a wide surface area, which is a benefit for chitosan nanoparticles, allowing them to be utilised to treat COVID-19. Our current studies reveal that nanoparticles may prove very helpful in the delivery of drugs for COVID-19 treatment. In recent studies, it has been seen that nanoparticles can prove very helpful in the delivery of drugs for COVID-19. In many cases, it has been observed that patients, where drugs are delivered with the help of nanoparticles, produced very few side effects. Several Drugs have been used to prevent COVID-19 infection including interferon α (IFN-α), lopinavir/ ritonavir, chloroquine J o u r n a l P r e -p r o o f phosphate, ribavirin, and arbidol. A new drug Favipiravir was also launched to treat COVID-19 in February 2021. These all drugs should be delivered into the human body at a specific range. Biopolymeric nanoparticles can be used to deliver these kinds of drugs by minimizing the risk of toxicity, with low solubility, and increasing feasible delivery of a drug. Chitosan nanoparticles will be the most emergent field to study drug delivery and novel drug discovery. In pulmonary drug delivery, drugs are administered directly to the lungs, offering a wide surface area, which is a benefit for chitosan nanoparticles, allowing them to be utilised to treat COVID-19. Our current studies reveal that nanoparticles may prove very helpful in the delivery of drugs for COVID-19 treatment. Nanomedicine science is one of the most exciting fields of research at the present time. The implementation of nanomedicine and of the nano-drug delivery system will certainly remain the future arena of research and development for many years, with the use of a variety of nanoparticles in the precise supply of drugs to the affected cells without disturbing the physiology of normal cells. Although the prospects for nanomedicine and the nano-drug system are overwhelmingly clear, their real effect is still very limited on the healthcare system, even in carcinogenic /diagnostics. The field is characterized by a new area of science, which only has real research on the subject over two decades and many key fundamental attributes are still unknown. One main area of research for the future is the fundamental marker of diseased tissues with key biological markers which enable absolute focusing without changing the normal cellular process. New natural biomaterials are continuing to be demanded for their biodegradability, biocompatibility, readiness for availability, renewability and low toxicity quality. Nano-biosensors can be used extensively for rapid detection of the viral disease. This work was supported through the industry-academia collaboration project, VtR Inc-CGU, R.O.C., project grant (SCRPD1L0221). J o u r n a l P r e -p r o o f Diagnosis and treatment of coronavirus disease 2019 (COVID-19): Laboratory, PCR, and chest CT imaging findings Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease Ribavirin and interferon therapy for critically ill patients with middle east respiratory syndrome: a multicenter observational study COVID-19 & Effectiveness towards it's available treatment Nanoparticle formulations in pulmonary drug delivery Drug delivery and cytocompatibility of ciprofloxacin loaded gelatin nanofibers-coated Mg alloy Hydroxychloroquine: from malaria to autoimmunity Influence of crosslinked alginate on drug release from highly concentrated emulsions Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase Strategies to modify the drug release from pharmaceutical systems Microemulsion utility in pharmaceuticals: Implications for multi-drug delivery COVID-19: towards understanding of pathogenesis In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings Chloroquine and hydroxychloroquine as available weapons to fight COVID-19 A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19 Origin and evolution of pathogenic coronaviruses Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection Evaluation of the physicochemical characteristics and activity of various kinds of ciprofloxacin HCl-loaded cationic nanoparticles Biopolymermediated green synthesis of noble metal nanostructures Coronaviruses: an overview of their replication and pathogenesis Anti-malarial drugs: possible mechanisms of action in autoimmune disease and prospects for drug development Mechanism of action of hydroxychloroquine as an antirheumatic drug Curcumin nanocapsules stabilized by bovine serum albumin-capped gold nanoclusters (BSA-AuNCs) for drug delivery and theranosis Pharmacokinetics and pharmacodynamics of cytochrome P450 inhibitors for HIV treatment The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus The effect of particle design on cellular internalization pathways Biodegradable long-circulating polymeric nanospheres A Review of COVID-19 (Coronavirus Disease-2019) Diagnosis, Treatments and Prevention CO2 bubble assisted layer-by-layer self-assembly of graphene oxide multilayer film Optimizing use of theranostic nanoparticles as a life-saving strategy for treating COVID-19 patients A simple improved desolvation method for the rapid preparation of albumin nanoparticles Chitosan-based spray-dried mucoadhesive microspheres for sustained oromucosal drug delivery Arguments in favour of remdesivir for treating SARS-CoV-2 infections Collagen and hyaluronic acid hydrogel in water-in-oil microemulsion delivery systems General and cardiac toxicity of doxorubicin-loaded gelatin nanoparticles Spray freeze drying of small nucleic acids as inhaled powder for pulmonary delivery. asian journal of pharmaceutical sciences Polymers for drug delivery systems Acetaminophen and ibuprofen dosing by parents A VEGF delivery system targeting MI improves angiogenesis and cardiac function based on the tropism of MSCs and layer-by-layer self-assembly Potential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicines Preparation of polymeric nanoparticles by novel electrospray nanoprecipitation COVID-19: consider cytokine storm syndromes and immunosuppression An overview of chitosan nanoparticles and its application in non-parenteral drug delivery Biopolymers-application in nanoscience and nanotechnology. Recent advances in biopolymers Development of electrosprayed mucoadhesive chitosan microparticles. Carbohydrate polymers Chitosan nanoparticles: a promising system in novel drug delivery Broad-spectrum in vitro activity and in vivo efficacy of the griffithsin against emerging viruses of the family Coronaviridae Population-based age-stratified seroepidemiological investigation protocol for coronavirus 2019 (COVID-19) infection Stem cell-extracellular vesicles as drug delivery systems: New frontiers for silk/curcumin nanoparticles Strategies in the design of nanoparticles for therapeutic applications Tackling COVID-19 pandemic through nanocoatings: Confront and exactitude. Current Research in Green and Sustainable Chemistry Chitosan nanoparticles: preparation, size evolution and stability The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak Pulmonary drug delivery: from generating aerosols to overcoming biological barriers-therapeutic possibilities and technological challenges. The lancet Respiratory medicine Biodegradable polymeric nanocarriers for pulmonary drug delivery Nanotechnology and the developing world Hybrid gelatin-based porous materials with a tunable multiscale morphology for tissue engineering and drug delivery New insights into the antiviral effects of chloroquine. The Lancet infectious diseases Diagnosis, treatment, and prevention of 2019 novel coronavirus infection in children: experts' consensus statement COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses Favipiravir, an anti-influenza drug against life-threatening RNA virus infections A nanostructured cell-free photosynthetic biocomposite via molecularly controlled layer-by-layer assembly Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo GS-5734) for the Treatment of Ebola and Emerging Viruses On Facing the SARS-CoV-2 (COVID-19) with Combination of Nanomaterials and Medicine: Possible Strategies and First Challenges Active freeze drying for production of nanocrystal-based powder: A pilot study Microparticle-embedded fibroin/alginate beads for prolonged local release of simvastatin hydroxyacid to mesenchymal stem cells Albumin nanoparticles with predictable size by desolvation procedure Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro Role of nanotechnology in diagnosing and treating COVID-19 during the Pandemic Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys Virological assessment of hospitalized patients with COVID-2019 Development of silk fibroin-derived nanofibrous drug delivery system in supercritical CO2 Mucoadhesive chitosan hydrogels as rectal drug delivery vessels to treat ulcerative colitis A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Chitosan: a versatile biomaterial Biodegradable nanoparticles containing doxorubicin-PLGA conjugate for sustained release Engineering biodegradable nanoparticles for drug and gene delivery Coagulopathy and antiphospholipid antibodies in patients with Covid-19 SARS-CoV-2: an emerging coronavirus that causes a global threat The novel coronavirus outbreak in Wuhan, China. Glob Health Res Policy Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China Nanotechnology against the novel coronavirus (severe acute respiratory syndrome coronavirus 2): diagnosis, treatment, therapy and future perspectives A comprehensive review of detection methods for SARS-CoV-2 J o u r n a l P r e -p r o o f CRediT authorship contribution statement NKC, D, RC, GAS, SM, RPP, and CMC were involved in the study's conceptualization and design. The material was organized and the initial draft of the manuscript was written by NKC, D, RC, GAS, SM, RPP, and CMC. NKC, RC, XL, RPP, and CMC contributed to the manuscript by writing portions and assisting with manuscript editing and formatting. All authors helped to revise the manuscript, read it, and approved the final version. Highlights  Almost every antiviral pharmaceutical system can be nano-scaled to improve its properties.  Nanoparticles as delivery vehicles can improve the effectiveness of drug delivery.  Nanomedicines and Nano-drug delivery system have shown promising effectiveness against the Covid 19 as treatments.  Numerous subsidies to advance the nanoparticular antiviral field are provided for public health and financially.